Wilson Sonsini is pleased to host the third session in our “Clinical AI and Health Tech: An Inflection Point” webinar series, featuring special guests Frank B. Meyers from the Federation of State Medical Boards (FSMB) and Shannon Curtis from the American Medical Association (AMA).
As AI takes on functions traditionally performed by licensed
On August 31, 2026, the Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) signed a memorandum of understanding (MOU) governing the sharing of nonpublic information relating to FDA-regulated products and activities. The MOU is not limited to enforcement matters and expressly contemplates the SEC’s use of FDA information in carrying
On September 16, 2026, Senators Elizabeth Warren (D-MA), Ron Wyden (D-OR), and Jeff Merkley (D-OR)—along with House companion sponsors Representatives Val Hoyle (D-OR), Suhas Subramanyam (D-VA), and Alexandria Ocasio-Cortez (D-NY)—introduced the Stop Corporate Takeovers of Physicians Act of 2026. Modeled after Oregon’s recent corporate practice of medicine (CPOM) law, the bill would, with
Artificial intelligence (AI)-enabled mental health products, including chatbots, digital companions, and coaching tools, are attracting increased attention from regulators, policymakers, and courts. Building on Wilson Sonsini’s previous alert, Legal Framework for AI in Mental Healthcare, this advisory discusses recent regulatory and litigation developments affecting these products, including new state laws on AI disclosure and
The Department of Justice (DOJ) has issued its first healthcare-related corporate declination under its revised Corporate Enforcement and Voluntary Self-Disclosure Policy, declining to prosecute a management services organization (MSO) while simultaneously indicting the former CEO and founder of the underlying optometry practice on healthcare fraud and Anti-Kickback Statute charges.
The alert provides background on the
Oregon’s Health Care Market Oversight (HCMO) program regulations underwent significant amendments that took effect on July 1, 2026, expanding which entities may qualify as “out-of-state” for HCMO purposes, narrowing the internal reorganization exclusion, and substantially increasing review fees. Preliminary review fees increased from $2,000 to $30,000, and comprehensive review fees increased to a range of